ArticleLife science alliance2022
The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health.
Article in Life science alliance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Guidelines for assessing maternal cardiovascular physiology during pregnancy and postpartum.American journal of physiology. Heart and circulatory physiology · 2024Guideline
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- USP22 suppresses trophoblast cell necroptosis in preeclampsia by stabilizing KAT2A-mediated histone acetylation at the SFRP1 promoter.Journal of translational medicine · 2026Article
- Impact of Dietary Salicylates on Iron, Zinc, and Copper Status in Preeclampsia Model Rats Induced by L-NAME.Biological trace element research · 2026Article
- Intestinal-targeted medicine-food homology ACE-inhibitory peptide microcapsules ameliorate hypertension in an L-NAME-induced gestational rat model via renin-angiotensin system modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cardiovascular complications of pregnancy.The Journal of clinical investigation · 2026Review
- The SIRT1-p53 axis drives a ferro-aging-like program and aggravates trophoblast dysfunction in preeclampsia.Frontiers in aging · 2026Article
- Hypertensive Pregnancy Disorders: From Mechanisms to Management.American journal of hypertension · 2026Review
- TRIM28-mediated p53 ubiquitination inhibits trophoblast apoptosis to support normal placental development.Open life sciences · 2026Article
- WTAP regulates NCOA4-mediated ferroptosis via a YTHDF2-dependent mechanism in preeclampsia.Clinical epigenetics · 2025Article
- AT1R autoantibody impedes fetal hepatic glycogen synthesis by inhibiting PI3K/AKT signaling pathway during late gestation.Journal of translational medicine · 2025Article
- Article
- Endoplasmic reticulum stress: an emerging therapeutic target for preeclampsia†.Biology of reproduction · 2025Review
- Article
- Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy.Scientific reports · 2025Article
- Investigating the Impact of Maternal Obesity on Disease Severity in a Mouse Model of Preeclampsia.Nutrients · 2025Article
- Pomegranate Juice Alleviates Preeclampsia Symptoms in an L-NAME-Induced Rat Model: A Dose-Dependent Study.Nutrients · 2025Article
- Article
- Activated PRDM1-CREBBP contributes to preeclampsia by regulating apoptosis and invasion of the human trophoblast cells.iScience · 2024Article
- Impacts of Maternal Preeclampsia Exposure on Offspring Neuronal Development: Recent Insights and Interventional Approaches.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia affects ∼2-8% of pregnancies worldwide. It is associated with increased long-term maternal cardiovascular disease risk. This study assesses the effect of the vasoconstrictor N(ω)-nitro-L-arginine methyl ester (L-NAME) in modelling preeclampsia in mice, and its long-term effects on maternal cardiovascular health. In this study, we found that L-NAME administration mimicked key characteristics of preeclampsia, including elevated blood pressure, impaired fetal and placental growth, and increased circulating endothelin-1 (vasoconstrictor), soluble fms-like tyrosine kinase-1 (anti-angiogenic factor), and C-reactive protein (inflammatory marker). Post-delivery, mice that received L-NAME in pregnancy recovered, with no discernible changes in measured cardiovascular indices at 1-, 2-, and 4-wk post-delivery, compared with matched controls. At 10-wk post-delivery, arteries collected from the L-NAME mice constricted significantly more to phenylephrine than controls. In addition, these mice had increased kidney
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.